Bio-Thera Solutions, Ltd. (SHA:688177)

Market Cap	9.23B +5.1%
Revenue (ttm)	933.69M +25.6%
Net Income	-336.44M
EPS	-0.81
Shares Out	414.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,331,813
Average Volume	2,158,374
Open	20.45
Previous Close	20.50
Day's Range	20.26 - 22.46
52-Week Range	18.92 - 36.32
Beta	0.53
RSI	49.27
Earnings Date	Apr 28, 2026

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epitheli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 1,266
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688177

Financial Performance

In 2025, Bio-Thera Solutions's revenue was 933.69 million, an increase of 25.64% compared to the previous year's 743.17 million. Losses were -336.44 million, -34.07% less than in 2024.